Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 62 of 76 for:    Long-chain fatty acids

Nutrition of Premature Infants With Human Breastmilk Fortifier (EFORT-LM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03191617
Recruitment Status : Recruiting
First Posted : June 19, 2017
Last Update Posted : March 28, 2019
Sponsor:
Information provided by (Responsible Party):
Patricia Mena Nannig, NEOCOSUR

Brief Summary:
The objective of the study is to compare two human milk fortifiers with different protein content and LCPUFA in a group of very low birth weight infants.

Condition or disease Intervention/treatment Phase
Growth Acceleration Dietary Supplement: Human milk fortifier Not Applicable

Detailed Description:
This study is a multi-center, third party-blinded, randomized, controlled, parallel- group, prospective trial comparing growth with a liquid human milk fortifier with higher protein content and LCPUFA and a control powdered human milk fortifier added to breast milk and fed to premature infants. The trial will be conducted in 11 centers in Chile. The enrollment period is expected to be approximately 18 months. To allow for dropouts, approximately 160 participants will be randomized.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Care Provider)
Primary Purpose: Treatment
Official Title: Nutrition of Premature Infants With Human Breastmilk Fortifier With Higher Protein Content and Long Chain Poli- Unsaturated Fatty Acids (LCPUFA)
Study Start Date : September 2015
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : December 2019

Arm Intervention/treatment
Experimental: Liquid human milk fortifier
Liquid human milk fortifier which has higher protein content and also LCPUFA
Dietary Supplement: Human milk fortifier
Fortification of breastmilk with liquid human milk fortifier in premature infants
Other Name: Mead Johnson´s Liquid Human Milk fortifier

Active Comparator: Powder human milk fortifier
Powder human milk fortifier with less protein content and no LCPUFA
Dietary Supplement: Human milk fortifier
Fortification of breastmilk with liquid human milk fortifier in premature infants
Other Name: Mead Johnson´s Liquid Human Milk fortifier




Primary Outcome Measures :
  1. Weight and linear growth [ Time Frame: between entering study and 45 days in study or discharge, whatever first ]
    Weight increase in g/K/day and knee-to-heel length increase in mm/weeks, measured in one scale (+-5 g) and one kneenometer (special device to measure longitude) (+- 1mm) by one person for each center between entering study and 45 days in study or discharge


Secondary Outcome Measures :
  1. Compare length of hospital- stay [ Time Frame: days from the first day of study to discharge home , an average of 37 weeks of postconceptual age ]
    days from the first day of study to discharge home ( weight is one criteria for discharge)

  2. Compare feeding tolerance [ Time Frame: Between entering study and 45 days in study or discharge, if discharge first ]
    Daily record of residue, regurgitation and suspend of gastric feedings

  3. Compare incidence of main preterm morbidities: necrotizing enterocolitis, bronchopulmonary dysplasia, retinopathy of prematurity and sepsis [ Time Frame: Between entering study and 45 days in study or discharge, if discharge is first ]
    Incidence of necrotizing enterocolitis grade II or more, bronchopulmonary dysplasia as additional oxygen at 36 postconceptual weeks, retinopathy of prematurity with treatment and sepsis with positive hemoculture

  4. Compare cost/benefits . The cost of use a fortificant and the benefit of growth velocity [ Time Frame: Between entering study and 45 days in study or discharge, if discharge is first ]
    compare cost of total amount of fortifier used compare with cost of number of days of hospitalization, number of days in neonatal intensive care unit in each group.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 40 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Premature infant equal or under 31 weeks gestational age at birth
  • Birth weight equal or under 1,250 g
  • Predominantly fed breast milk (mother's milk or donor milk) on study day 0
  • Appropriate birth weight for gestational age (AGA) - defined as birth weight between and inclusive of the 10th and 90th percentiles on the Fenton growth chart
  • Singleton or twin birth (both twins do not need to qualify and be randomized into study)
  • Birth weight is ≤1,000 g and participant is ≤ 40 days of age on study day 0
  • Birth weight is above 1,000 g and participant is ≤ 30 days of age on study day 0
  • Enteral intake of 80 mL/kg/d of unfortified breast milk on study day 0
  • Anticipate mother`s willingness to breast milk for at least 28 days from study day 0
  • Signed informed consent obtained

Exclusion Criteria:

  • History of underlying metabolic or chronic disease, congenital malformation, or any other condition which, in the opinion of the Investigator, is likely to interfere with: the ability of the participant to ingest food, normal growth and development of the participant, or the evaluation of the participant
  • 5 minute APGAR score ≤ 4
  • Major surgery that required general anesthesia prior to first day study (note: persistent ductus arterious ligation is allowed)
  • Received pharmacologic doses of glucocorticoids during 3 consecutive days (72 hours) prior to or on day one of study (physiologic hydrocortisone administration up to 1.5 mg/kg/d is permitted)
  • Ventilator-dependent and requiring ≥ 40% fraction of inspired oxygen (FiO2) on day one of study (ventilator dependent and requiring ≤ 40% FiO2 and/or nasal canula, and/or nasal continous positive airway pressure (CPAP) and/or oxygen hood is allowed)
  • Grade III or IV bilateral intraventricular hemorrhage (IVH) prior to or on study day one
  • Feeding intolerance to breast milk feedings on study day one
  • Consumption of more than 3 feedings or 12 hours of continuous feeds of fortified breast milk prior to study day one
  • Fluid restriction < 120 mL/kg/d
  • History of creatinine >2.0 mg/dL 7 days prior to or on study day one
  • Currently receiving or plan use of probiotics

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03191617


Contacts
Layout table for location contacts
Contact: Daniela Masoli, MD 56-9-95453952 daniela.masoli@gmail.com

Locations
Layout table for location information
Chile
Pontificia universidad Catolica de Chile Recruiting
Santiago, Metropolitana, Chile, 8330024
Contact: JOSE L TAPIA, MD    56-9-92318797    jlta@med.puc.cl   
Sponsors and Collaborators
NEOCOSUR
Investigators
Layout table for investigator information
Principal Investigator: Patricia Mena, MD Hospital Sotero del Rio

Layout table for additonal information
Responsible Party: Patricia Mena Nannig, MD, NEOCOSUR
ClinicalTrials.gov Identifier: NCT03191617     History of Changes
Other Study ID Numbers: NEOCOSUR
First Posted: June 19, 2017    Key Record Dates
Last Update Posted: March 28, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided